Seqirus has public health protection at its core, reflecting the promise of our parent company, CSL Limited, founded in 1916 to save lives and protect the health of people. Together with our partners on the front line, we have served Australia’s healthcare needs for over a century. Today we develop, manufacture and source medicines that support the health and well-being of many thousands of people around the world. Seqirus operates Australia’s only local manufacturing facility for seasonal and pandemic influenza vaccine, and produces a range of unique medicines in the national interest including antivenoms and Q fever vaccine. Seqirus also in-licenses a broad range of paediatric and adult vaccines and specialty pharmaceutical products including 

Ryaltris® (Olopatadine hydrochloride & Mometasone furoate monohydrate) Nasal Spray, 
Acarizax® (American house dust mite extract & European house dust mite extract) Sublingual Tablets and 
Grazax® (Phelum pretense) Sublingual Tablets.

 

RYALTRIS® is a registered trade mark of Glenmark Specialty S.A. ACARIZAX® & GRAZAX® are registered trademarks of ALK-Abelló A/S, used under licence. Seqirus™ is a trademark of Seqirus UK Limited or its affiliates. ABN 66 120 398 067. Seqirus (Australia) Pty Ltd, Melbourne, Australia. www.seqirus.com.au Medical Information: 1800 642 865.